Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-9 (Cancelled)

10. (Currently Amended) A method for treating in a human being diffuse macular edema in diabetic maculopathy comprising administering to the human subject having diabetic maculopathy with diffuse macular edema an effective amount of a compound represented by the following general formula and ameliorating the diffuse macular edema by the administration:

wherein X represents a halogen or a hydrogen atom, and R¹ and R² concurrently or differently represent a hydrogen atom or a C1 to C6 alkyl group.

- 11. (Currently Amended) The method for treating in a human being diffuse macular edema in-diabetic maculopathy according to claim 10, wherein the compound is administered in the form of an oral agent.
- 12. (Currently Amended) The method for treating in a human being diffuse macular edema in-diabetic maculopathy according to claim 10, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.

13. (Cancelled)

14. (Previously Presented) A method for improving visual acuity and inhibiting a deterioration of visual acuity in diabetic maculopathy comprising the method according to claim 10.

Claims 15-17 (Cancelled)

18. (New) A method for treating diabetic maculopathy comprising administering to a human subject having diabetic maculopathy with diffuse macular edema an effective amount of a compound represented by the following general formula, ameliorating the diffuse macular edema by the administration, and consequently inhibiting a deterioration of visual acuity of the subject:

wherein X represents a halogen or a hydrogen atom, and R¹ and R² concurrently or differently represent a hydrogen atom or a C1 to C6 alkyl group.

- 19. (New) The method for treating diabetic maculopathy according to claim 18, further comprising improving visual acuity of the subject finally.
- 20. (New) The method for treating diabetic maculopathy according to claim 18, wherein the compound is administered in the form of an oral agent.

21. (New) The method for treating diabetic maculopathy according to claim 18, wherein the compound is (2S, 4S)- 6-fluoro- 2',5'-dioxospiro [chroman-4,4'-imidazolidine]- 2-carboxamide.